Seeking Alpha

Aegis lifts target on Ampio Pharmaceuticals

  • Aegis is out with some upbeat commentary on Ampio Pharmaceuticals (AMPE -1.7%) on the heels of the company's announcement that a subsidiary has struck research agreements with Western Galilee Medical Center and the University of Thessaly where researchers will "utilize Luoxis' proprietary RedoxSYS ORP diagnostic system to study oxidative stress markers across hypertension, hemodialysis, sepsis, and physical exertion." (PR)
  • Additionally, analyst Selvaraju thinks "the company should be able to file for approval [for Ampion] with positive data from a single Phase 3 confirmatory trial."
  • Price target hiked to $15 from $14.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: